• Explore /
  • Poster
  • / A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

Abstract Poster

Authors

Frederic Reu

Frederic J. Reu

Cleveland Clinic, Cleveland, OH

Frederic J. Reu , Dale Grabowski , Reda Z. Mahfouz , Hillard M. Lazarus , Robert M. Dean , Beth Faiman , Janice Reed , Mary Ann Karam , Kimberly Hamilton , Sherry Fada , Matt E. Kalaycio , Jason Neil Valent , Christy Joy Samaras , Ronald M. Sobecks , Linda McCowen , Jamie Elberson , Hien Liu , Yogen Saunthararajah , Yap Chew , Mitchell R. Smith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01155583

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8584)

DOI

10.1200/jco.2015.33.15_suppl.8584

Abstract #

8584

Poster Bd #

402

Abstract Disclosures

Similar Posters

First Author: James R. Berenson

First Author: Dan T. Vogl

First Author: Cristina Gasparetto

First Author: Andrew Jenho Yee